ctDNA Liquid Biopsy Test - InVision First-Lung
ctDNA Liquid Biopsy Test

InVisionFirst®-Lung, a ctDNA NGS liquid biopsy testing 37 genes relevant to the care of patients with advanced NSCLC

Focused - 37 gene panel including NSCLC markers
Actionable - Largest prospective molecular diagnostics study in NSCLC published up to date in JCO Precision Oncology
Sensitive & Specific - Our technology brings high sensitivity and specificity to drive appropriate treatment choice
Timely Results - Results within 7 calendar days from blood draw

Covered for Medicare and other private insurance NSCLC patients who meet specific clinical criteria in the United States.

InVisionFirst-Lung® is available world-wide for both commercial and research use.

Focused - Support the prognosis and therapeutic decisions in patients diagnosed with NSCLC

37 gene panel including NSCLC markers

Supports the therapeutic decisions in patients diagnosed with advanced non-small cell lung cancer (NSCLC)

ALK BRAF EGFR ERBB2 (HER2) RET
KRAS MET ROS1 STK11 NTRK1
VIEW FULL GENE LIST

Alterations associated with:
a) an FDA approved drug for another tumor type,
b) inclusion or exclusion criteria for clinical trials and/or,
c) indicators for resistance to therapy.

 

AKT1 CCND1 CDKN2A CTNNB1 ESR1 FGFR1 FGFR2
FGFR3 GATA3 GNA11 GNAQ GNAS HRAS IDH1
IDH2 KIT MAP2K1 MYC NFE2L2 NRAS NTRK3
PDGFRA PIK3CA PPP2R1A PTEN TP53 U2AF1
SNVs + Indels - Hotspot Regions
Fusions + SNVs + Indels
CNVs + SNVs + Indels
Fusions
10 actionable genes relevant to advanced NSCLC  in a panel of 37 genes

  • ALK, BRAF, EGFR, NTRK1, RET, ROS1 for FDA-approved targeted therapies
  • MET and ERBB2 (HER2) as recommended by CAP/AMP/ASCO/IASLC guidelines
  • KRAS and STK11 for prognostic and therapeutic value as described in clinical literature
Actionable - 26% more actionable alterations  detected versus standard-of-care tissue testing

Largest prospective molecular diagnostics study in NSCLC published up to date in JCO Precision Oncology

98% concordance

observed with matched tissue profiling

InVisionFirst-Lung provided access to comprehensive genetic profiling (CGP) when tissue was not available

26% more actionable alterations

detected versus standard-of-care tissue testing

Sensitive & Specific - a detection range as low as 0.1% variant allele fraction with a mean read depth of 70,000.

Our technology brings high sensitivity and specificity to drive appropriate treatment choice

Liquid Biopsy detects SNVs, InDels, CNVs and SV

InVision® Platform can detect single nucleotide variants (SNVs), small insertions and deletions (InDels), copy number variant (CNVs), and structural variants (SV) such as fusions from plasma cell free DNA (cfDNA) with a detection range as low as 0.1% variant allele fraction with a mean read depth of 70,000.

Click here for InVisionFirst®-Lung clinical validation results and clinical utility data.

Timely Results - The report includes genetic alterations and corresponding recommended therapeutics, such as assessment of predicted response to treatments and available to currently enrolling clinical trials

Results within 7 calendar days from blood draw

Sample InVisionFirst-Lung clinical report
  • Test results are delivered through a secure Clinician Portal
  • The report includes genetic alterations and corresponding recommended therapeutics, such as assessment of predicted response to treatments and available to currently enrolling clinical trials
  • This report can be easily exported and added to most electronic health records (EHRs)

InVisionFirst®-Lung can help at different stages:

At Diagnosis*

  • When results for EGFR single nucleotide variants (SNVs) and insertions and deletions (indels); rearrangements in ALK, NTRK1, RET and ROS1; and SNVs for BRAF are not available AND
  • When tissue-based CGP is infeasible (i.e. quantity not sufficient (QNS) for tissue-based CGP or invasive biopsy is medically contraindicated).

OR

At Progression*

  • For patients progressing on or after chemotherapy or immunotherapy who have not been tested for EGFR SNVs and indels; rearrangements in ALK, NTRK1, RET and ROS1; and SNVs for BRAFs, and for whom tissue-based CGP is infeasible; OR
  • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs).

* If no genetic alteration is detected by InVisionFirst®-Lung or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered

Our Technology

Our Solutions

Latest News